Oncolytics Biotech (NASDAQ:ONCY) Issues Quarterly Earnings Results

Key Points

• Oncolytics Biotech reported quarterly earnings of ($0.05) per share, surpassing the expected ($0.11) by $0.06.
• The stock currently has a market cap of $83.62 million and a consensus target price of $4.33.
• Analysts have a mixed outlook with one hold rating and three buy ratings, while HC Wainwright has set a price objective of $5.00 for the shares.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.06, Zacks reports.

Oncolytics Biotech Stock Performance

ONCY opened at $0.86 on Friday. The stock has a market cap of $83.62 million, a price-to-earnings ratio of -3.18 and a beta of 1.09. The stock's 50 day moving average price is $0.86 and its 200-day moving average price is $0.69. Oncolytics Biotech has a one year low of $0.33 and a one year high of $1.53.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ONCY shares. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research note on Wednesday, May 21st. Jones Trading reaffirmed a "hold" rating on shares of Oncolytics Biotech in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $4.33.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.